Anupam Rasayan India Ltd has announced its entry into the formulations business through the acquisition of Bliss GVS Pharma Ltd in a deal valued at Rs 1369 crore. The acquisition marks a major strategic move for Anupam Rasayan as it looks to strengthen its position in the pharmaceutical and healthcare sector while expanding beyond its traditional specialty chemicals operations.
The company stated that the acquisition will help create a broader and more diversified business model with a stronger presence in high growth pharmaceutical formulations. Bliss GVS Pharma is known for its expertise in suppositories pessaries and other dosage forms with operations across domestic and international markets.
Industry experts believe the acquisition could open new opportunities for Anupam Rasayan by giving it access to established pharmaceutical manufacturing capabilities along with a global distribution network. The move also reflects the growing trend of Indian chemical companies expanding into value added healthcare businesses to improve margins and create long term growth opportunities.
Company officials said the acquisition is expected to generate operational synergies through integrated manufacturing research capabilities and supply chain efficiencies. The combined business is likely to benefit from increasing demand for pharmaceutical products in both emerging and developed markets.
The deal comes at a time when India’s pharmaceutical sector continues to attract strong investor interest due to rising healthcare spending and expanding export opportunities. Analysts believe the acquisition may strengthen Anupam Rasayan’s competitive position and support its future expansion plans in the healthcare industry.
Market participants will now closely watch how the integration process unfolds and how the company leverages the acquisition to drive growth in the formulations segment.
